navitoclax + paclitaxel

Navitoclax + paclitaxel is an **investigational combination therapy** composed of navitoclax, an orally bioavailable, small molecule inhibitor of the anti-apoptotic Bcl-2 family proteins (notably BCL-2, BCL-XL, and BCL-W), and paclitaxel, a well-established antimicrotubule agent that stabilizes microtubules and inhibits cell division. Navitoclax enhances apoptosis by lowering the apoptotic threshold in cancer cells, potentially overcoming chemotherapy resistance when used with agents like paclitaxel. The combination has been studied in solid tumors and ovarian cancer, aiming to achieve synergy by targeting complementary mechanisms—the intrinsic apoptotic pathway and mitotic arrest. Clinical development has been limited by toxicity and modest efficacy[1][5][3].

Other names

ABT-263 + paclitaxel